Key Highlights
- Shares are trading down 3.55% to $46.16, giving back an earlier pre-market pop.
- The company formally submitted a Biologics License Application to the FDA, requesting priority review, and a Marketing Authorisation Application to the UK's MHRA for its Huntington's disease gene therapy.
- The filings are supported by three-year Phase I/II data and backed by Breakthrough Therapy, RMAT, and Fast Track designations.
- William Blair initiated coverage with an Outperform rating and a $73 price target, adding to an already bullish analyst base of 11 buy-equivalent ratings and no sells.
- Shares remain up roughly 175% over the past year from their 52-week low, even after today's pullback.
Shares Retreat Even as a Major Regulatory Milestone Is Announced
uniQure (NASDAQ:QURE) is trading lower today even after submitting a Biologics License Application to the U.S. Food and Drug Administration and a Marketing Authorisation Application to the UK's Medicines and Healthcare products Regulatory Agency for its Huntington's disease gene therapy, a reaction that runs counter to what would typically be viewed as strongly positive news. The company requested priority review for the U.S. filing, which, if granted, would shorten the FDA's review cycle to six months following the agency's standard 60-day filing review period.
The submissions are supported by a previously announced three-year data analysis from the drug's Phase I/II clinical program, compared against an external control population, and are backed by Breakthrough Therapy, Regenerative Medicine Advanced Therapy, and Fast Track designations from the FDA.
Fresh Analyst Coverage Reinforces the Bullish Case
The regulatory filing was reinforced by a new Outperform rating and $73 price target from a major research firm, adding to an already bullish analyst base of 11 buy-equivalent ratings and no sell ratings. Despite this supportive backdrop, the stock is giving back a portion of its earlier gains, suggesting today's decline reflects profit-taking rather than any concern about the regulatory news itself.
Profit-Taking and Macro Pressure Appear to Explain the Decline
The pullback comes amid broader market pressure from surging bond yields and renewed geopolitical tensions in the Middle East, and follows a sharp run-up in the shares that saw them touch an intraday high earlier in the session. Even after today's decline, the stock remains up roughly 175% over the past year from its 52-week low, leaving room for near-term profit-taking after an extended rally, independent of the underlying regulatory progress.
Regulatory Review Timeline Becomes the Next Watch Point
With both the U.S. and UK filings now submitted, investor attention shifts to the FDA's 60-day filing review and the potential granting of priority review, alongside a four-year data analysis the company plans to present later this quarter. Today's share-price decline appears to reflect near-term profit-taking rather than any doubt about the underlying regulatory submission.






Please wait processing your request...